CALLE DOCTOR FLEMING, 51 | 28036 MADRID, SPAIN
+34 91 3459395 | +44 (0) 20 3951 8071
info@oxonepi.com

OXON AT ICPE Conference – 24-28 August2022

ICPE2022

OXON’s real-world studies at the 38th International Conference on PharmacoEpidemiology, ICPE 2022. 

Advancing Pharmacoepidemiology and Real-World Evidence for the Global Community

August 24-28, 2022 | Bella Center Copenhagen | Copenhagen, Denmark

At OXON we are excited to be supporting ICPE 2022 as an exhibitor, presenting our capabilities and research during this in-person event for scientific and informal interaction.

One year more, OXON is pleased to inform you that we will be In-person at the Bella Convention Center, Copenhagen, Denmark, exhibiting and presenting at the 38th International Conference on PharmacoEpidemiology.

During  the conference, we will be at booth #105 looking forward to welcoming you to discuss how we can help with your needs for creative and proven world-class approaches to real-world field and secondary data studies, in all major therapy areas.

Come visit us and find out how we can help you optimize your investment in real-world evidence and support you to effectively meet your real-world data requirements for Safety, Market access and Clinical development.  We invite you to come and explore our services approaches, designs and implementation options for international field, database, and hybrid Real World Evidence studies.

Our team will demonstrate our record of achievements to provide you cost-effective solutions, including the following:

  • 100% approval record of PASS, PAES, risk minimization (including ‘rescue’) and hybrid pregnancy studies
  • External controls for regulatory and HTA submissions of orphan drugs
  • Studies with collection of retrospective/prospective biospecimens
  • Recent publications (including Lancets)

Late Breaking Poster:
Learning from disappointing results of RW studies for Covid, for the conduct of future RW studies

  • Poster Session B:  Saturday, August 27, Hall C
    (257) [931] Totality of Evidence Evaluating the Effectiveness of Repurposed Therapies for COVID19: What Can We Learn from Real-World Studies & Randomized Controlled Trials?
    Collaboration with Gate Foundation.

Poster presentation:

  • Poster Session A:  Friday, 26 August 2022, Hall C
    (129) [460] Validity of adverse clinical outcomes in routine health data for COVID-19 vaccines and therapies

Notable recent publications:
Blood cholesterol and risk of dementia in more than 1·8 million people over two decades: a retrospective cohort study.
Masao Iwagami, Nawab Qizilbash, John Gregson, Prof Ian Douglas, Michelle Johnson, Prof Neil Pearce, Prof. Stephen Evans, Prof. Stuart Pocock. Lancet Healthy Longevity 2021.